These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 19846844)

  • 1. A novel influenza A (H1N1) vaccine in various age groups.
    Zhu FC; Wang H; Fang HH; Yang JG; Lin XJ; Liang XF; Zhang XF; Pan HX; Meng FY; Hu YM; Liu WD; Li CG; Li W; Zhang X; Hu JM; Peng WB; Yang BP; Xi P; Wang HQ; Zheng JS
    N Engl J Med; 2009 Dec; 361(25):2414-23. PubMed ID: 19846844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial.
    Liang XF; Wang HQ; Wang JZ; Fang HH; Wu J; Zhu FC; Li RC; Xia SL; Zhao YL; Li FJ; Yan SH; Yin WD; An K; Feng DJ; Cui XL; Qi FC; Ju CJ; Zhang YH; Guo ZJ; Chen PY; Chen Z; Yan KM; Wang Y
    Lancet; 2010 Jan; 375(9708):56-66. PubMed ID: 20018364
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Response to a monovalent 2009 influenza A (H1N1) vaccine.
    Greenberg ME; Lai MH; Hartel GF; Wichems CH; Gittleson C; Bennet J; Dawson G; Hu W; Leggio C; Washington D; Basser RL
    N Engl J Med; 2009 Dec; 361(25):2405-13. PubMed ID: 19745216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of a monovalent 2009 influenza A(H1N1) vaccine in infants and children: a randomized trial.
    Nolan T; McVernon J; Skeljo M; Richmond P; Wadia U; Lambert S; Nissen M; Marshall H; Booy R; Heron L; Hartel G; Lai M; Basser R; Gittleson C; Greenberg M
    JAMA; 2010 Jan; 303(1):37-46. PubMed ID: 20026597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
    Clark TW; Pareek M; Hoschler K; Dillon H; Nicholson KG; Groth N; Stephenson I
    N Engl J Med; 2009 Dec; 361(25):2424-35. PubMed ID: 19745215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H; Furuie H; Yasuda Y; Komatsu R; Matsushita K; Minami T; Suehiro Y; Yotsuyanagi H; Kusadokoro H; Sawata H; Nakura N; Lattanzi M
    Vaccine; 2012 Jul; 30(33):5030-7. PubMed ID: 22472791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to <18 years of age: a prospective, open-label, multi-center trial.
    Oh CE; Lee J; Kang JH; Hong YJ; Kim YK; Cheong HJ; Ahn YJ; Kim SH; Lee HJ
    Vaccine; 2010 Aug; 28(36):5857-63. PubMed ID: 20600483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 influenza vaccine in children 3 to < 9 years of age.
    Nassim C; Christensen S; Henry D; Holmes S; Hohenboken M; Kanesa-Thasan N
    Pediatr Infect Dis J; 2012 Apr; 31(4):e59-65. PubMed ID: 22418661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial to identify the optimal antigen and MF59(®) adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly subjects.
    Hatz C; von Sonnenburg F; Casula D; Lattanzi M; Leroux-Roels G
    Vaccine; 2012 May; 30(23):3470-7. PubMed ID: 22446638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I and II randomised trials of the safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in healthy adults.
    Nolan TM; Richmond PC; Skeljo MV; Pearce G; Hartel G; Formica NT; Höschler K; Bennet J; Ryan D; Papanaoum K; Basser RL; Zambon MC
    Vaccine; 2008 Aug; 26(33):4160-7. PubMed ID: 18599164
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and tolerability of an MF59-adjuvanted, egg-derived, A/H1N1 pandemic influenza vaccine in children 6-35 months of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Pediatr Infect Dis J; 2014 Dec; 33(12):e320-9. PubMed ID: 24978857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of varying dosages of a monovalent 2009 H1N1 influenza vaccine given with and without AS03 adjuvant system in healthy adults and older persons.
    Jackson LA; Chen WH; Stapleton JT; Dekker CL; Wald A; Brady RC; Edupuganti S; Winokur P; Mulligan MJ; Keyserling HL; Kotloff KL; Rouphael N; Noah DL; Hill H; Wolff MC
    J Infect Dis; 2012 Sep; 206(6):811-20. PubMed ID: 22782949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of an AS03-adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a seasonal trivalent vaccine in adults 61 years or older: data from two multicentre randomised trials.
    Peeters M; Regner S; Vaman T; Devaster JM; Rombo L
    Vaccine; 2012 Oct; 30(45):6483-91. PubMed ID: 22885014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials.
    Plennevaux E; Sheldon E; Blatter M; Reeves-Hoché MK; Denis M
    Lancet; 2010 Jan; 375(9708):41-8. PubMed ID: 20018365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.